Polymer(Korea) (폴리머)

The Polymer Society of Korea (한국고분자학회)
권호 표지

Characteristics of BCNU-loaded PLGA Wafers

BCNU를 함유한 생분해성 PLGA 웨이퍼의 특성분석

  • 안태군 (전북대학교 유기신물질공학과) ;
  • 강희정 (전북대학교 유기신물질공학과) ;
  • 이진수 (전북대학교 유기신물질공학과) ;
  • 성하수 (한국화학연구원 생체고분자연구실) ;
  • 정제교 (삼천당제약 중앙연구소)
  • Published : 2002.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

Interstitial therapy using biodegradable polymeric device loaded with anticancer agent can deliver the drug to the tumor site at high concentration, resulting in an increase of therapeutic efficacy. 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU, carmustine) is most commonly used as chemotherapeutic agent for brain tumors. The design of implantable device is regarded as an important factor lot the efficient delivery of antitumor agent to targeting site. In order to control the release profile of drug, the release pattern of BCNU with the changes of various dimension and additives was investigated. The PLGA wafers containing 3.85, 10, 20 and 30% of BCNU were prepared in various shape (diameter of 3, 5 and 10 mm, thickness of 0.5, 1 and 2 mm) by direct compression method. In vitro drug release profile of BCNU-loaded PLGA wafers could be controlled by changing the dimension of wafers such as initial drug content, weight, diameter, thickness, volume and surface area of wafers, as well as PLGA molecular weight and additives. Drug release from BCNU-loaded PLGA wafers was facilitated with an increase of BCNU-loading amount or presence of poly(N-vinylpyrrolidone)(PVP) or sodium chloride (NaCl). The effects of various geometric factors and additives on the BCNU release pattern were confirmed by the investigation of mass loss and morphology of BCNU-loaded PLGA wafers.

항암제가 함유된 생분해성 고분자 디바이스를 이용한 국소전달요법은 종양 부위에 고농도로 약물을 전달시킬 수 있는 이유로 약물의 효율성을 증가시킬 수 있다. 1,3-bis(2-chloroethyl)-1-nitro-sourea (BCNU, carmustine)는 뇌종양 치료를 위하여 가장 일반적으로 사용되는 화학요법적 약물이다. 표적 부위까지 항암제를 효과적으로 전달하기 위한 이식제의 설계는 중요한 인자이다. 본 연구에서 약물의 방출경향을 조절하기 위해서 생분해성 웨이퍼의 첨가제와 다양한 제형 변화로부터 BCNU의 방출패턴을 조사하였다. 각각 3.85, 10, 20 및 30%의 BCNU를 함유한 PLGA 웨이퍼를 다양한 형태(직경 3, 5 및 10 mm, 두께 0.5, 1 및 2 mm)로 직접 압축성형법에 의해 제조하였다. 생체외 방출실험에서 BCNU 함유 PLGA 웨이퍼로부터 약물 방출거동은 웨이퍼의 포기 약물 함유량, 무게, 직경, 두께, 부피, 표면적 및 PLGA 분자량뿐만 아니라 첨가제의 종류와 같은 다양한 변수로 조절했다. 웨이퍼로부터 약물의 방출은 BCNU 함유량 및 염화나트륨 (NaCl)과 폴리엔비닐피롤리돈 (PVP)이 증가할수록 촉진되었다. 또한, BCNU가 함유된 PLGA 웨이퍼의 무게와 형태변화에 대한 조사를 통하여 다양한 기하학적 인자들과 첨가제의 효과를 고찰하였다.

Keywords

References

  1. Biomater.Res. v.4 D.S. Moon;G. Khang;H.S. Seong;J.M. Rhee;J.S. Lee;H.B. Lee
  2. N.Eng.J.Med. v.324 P.M. Black https://doi.org/10.1056/NEJM199105233242105
  3. Neurosurgery v.23 R.E. Harbaugh;R.L. Sanders;R.F. Reeder https://doi.org/10.1227/00006123-198812000-00001
  4. J.Neurosurg. v.83 R.D. Penn;M.M. York;J.A. Paice https://doi.org/10.3171/jns.1995.83.2.0215
  5. Brain Res. v.674 J. Kreuter;R.N. Alyautdin;D.A. Kharkevich;A.A. Ivanov https://doi.org/10.1016/0006-8993(95)00023-J
  6. Adv.Drug Deliv.Rev. v.10 U. Bickel;T. Yoshikawa;W.M. Pardridge https://doi.org/10.1016/0169-409X(93)90048-9
  7. Acta Neurol.Scand. v.126 O. Lindvall;A. Bjorklund
  8. Neuroscience v.23 F.H. Gage;J.A. Wolff;M.B. Rosenberg;L. Xu;J.K. Yee;C. Shults;T. Friedmann https://doi.org/10.1016/0306-4522(87)90159-X
  9. Biomedical Polymer G. Khang;H.B. Lee
  10. Korea Polym.J. v.7 J.C. Cho;G. Khang;J.M. Rhee;Y.S. Kim;J.S. Lee;H.B. Lee
  11. Bio-Med.Mater.Eng. v.9 G. Khang;J.C. Cho;J.W. Lee;J.M. hee;H.B. Lee
  12. Polymer Preprints v.40 H.B. Lee;G. Khang;J.C. Cho;J.M. Rhee;J.S. Lee
  13. Korea Polym.J. v.8 G. Khang;J.H. Lee;J.W. Lee;J.C. Cho;H.B. Lee
  14. Polymer(Korea) v.24 J.C. Cho;G. Khang;H.S. Choi;J.M. Rhee;H.B. Lee
  15. Biomater.Res. v.4 W.I. Son;D.I. Yun;G. Khang;B.S. Kim;H.B. Lee
  16. Biomater.Res. v.4 J.C. Cho;G. Khang;J.M. Rhee;Y.S. Kim;J.S. Lee;H.B. Lee
  17. Polymer(Korea) v.25 S.A. Seo;H.S. Choi;D. Lee;J.M. Rhee;H.B. Lee
  18. Biomater.Res. v.5 S.A. Seo;H.S. Choi;J.C. Cho;G. Khang;J.M. Rhee;H.B. Lee
  19. Int.J.Pharm. v.234 H.S. Choi;G. Khang;H.C. Shin;J.M. Rhee;H.B. Lee https://doi.org/10.1016/S0378-5173(01)00968-1
  20. Int.J.Pharm. v.239 S.A. Seo;H.S. Choi;J.C. Cho;G. Khang;J.M. Rhee;H.B. Lee https://doi.org/10.1016/S0378-5173(02)00074-1
  21. ACS Symp.Series 752 Fentanyl-loaded PLGA microspheres for local anesthesia ; Controlled Drug Delivery;Designing Technologies for the Future H.B. Lee;G. Khang;J.C. Cho;J.M. Rhee;J.S. Lee;K. Park(ed.);R.J. Mrnsy(ed.)
  22. Cancer Res. v.53 R.J. Tamargo;J.S. Myseros;J.I. Epstein;M.B. Jang;M. Chasin;H. Brem
  23. Cancer Res. v.54 K.A. Walter;M.A. Cahan;A. Gur;B. Tyler;J. Hilton;O.M. Colvin;P.C. Burger;A. Domb;H. Brem
  24. Neurosurgery v.39 K.O. Lillehei;Q. Kong;S.J. Withrow;B. Kleinschmidts https://doi.org/10.1097/00006123-199612000-00023
  25. Neurosurgery v.39 P. Minie;M. Boisdron-Cller;A. Croue;G. Guy;J.P. Benoit https://doi.org/10.1097/00006123-199607000-00023
  26. J.Neurosurg. v.74 H. Brem;M.S. Mahaley;N.A. Vick;K.L. Black;S.C. Schold;T.W. Ellier;J.W. Cozzens;J.N. Kenealy https://doi.org/10.3171/jns.1991.74.3.0441
  27. J.Neuro-Oncol. v.26 H. Brem;M.G. Ewend;S. Piantadosi;J. Greenhoot;P.C. Burger;M. Sisti https://doi.org/10.1007/BF01060217
  28. Polymer Sci.Tech. v.12 G. Khang;J.M. Rhee;J.S. Lee;H.B. Lee
  29. Macromol.Chem.Symp. v.14 H.S. Seong;D.S. Moon;G. Khang;H.B. Lee
  30. Polymer(Korea) v.26 H.S. Seong;D.S. Moon;G. Khang;H.B. Lee
  31. Polymer(Korea) v.26 T.K. An;H.J. Kang;D.S. Moon;J.S. Lee;H.S. Seong;J.K. Jeong;G. Khang;H.B. Lee
  32. Drug.Dev.Ind.Pharm. v.22 M. Iwata;H. Ueda https://doi.org/10.3109/03639049609065953
  33. Chin.Pharm.J. v.30 W.G. Lu;Y. Zhang;Q.M. Xiong;Y.C. Bao;Q.H. Chen
  34. Indian Drugs v.32 K.P. Chowdary;K.V. Ramesh
  35. J.Pharm.Sci. v.55 T.L. Loo;R.L. Dion;R.L. Dixon;D.P. Rall https://doi.org/10.1002/jps.2600550509
  36. Acta Pharm.Scand. v.23 K. Fredrikson;P. Lundgren
  37. J.Pharm.Sci. v.56 S. Leigh;J.E. Carless;B.W. Burt https://doi.org/10.1002/jps.2600560721
  38. Int.J.Pharm. v.149 I.S. Moussa;L.H. Cartilier https://doi.org/10.1016/S0378-5173(97)04864-3
  39. Int.J.Pharm. v.158 P. Shivan;O.L. Sprokel
  40. Int.J.Pharm. v.88 S. Trikkonen;P. Paronen https://doi.org/10.1016/0378-5173(92)90302-I
  41. Int.J.Pharm. v.92 S. Trikkonen;P. Paronen https://doi.org/10.1016/0378-5173(93)90263-F
  42. J.Pharmacol. v.33 C. McDonald;C. Richardson https://doi.org/10.1111/j.2042-7158.1981.tb13698.x